论文部分内容阅读
目的观察瑞格列奈治疗2型糖尿病的疗效。方法 61例2型糖尿病患者随机分为治疗组和对照组。两组患者均给以控制饮食、运动疗法等基础治疗。治疗组同时予瑞格列奈1mg餐前15min口服,3次/d。连续治疗12周。观察对比两组治疗前后的空腹血糖(FBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)等变化,并记录药物的不良反应。结果治疗组总有效率为87.1%,对照组总有效率为43.3%,治疗组疗效高于对照组(P<0.01)。治疗组在治疗后空腹血糖、餐后2h血糖、糖化血红蛋白均较治疗前明显降低,差异有显著性(P<0.01或P<0.05),且较对照组明显(P<0.01或P<0.05)。未观察到药物有明显不良反应。结论瑞格列奈可以有效控制血糖,保护胰岛β细胞功能,是临床治疗2型糖尿病的理想药物。
Objective To observe the effect of repaglinide on type 2 diabetes mellitus. Methods Sixty-one patients with type 2 diabetes were randomly divided into treatment group and control group. Two groups of patients were given to control the diet, exercise therapy and other basic treatment. The treatment group at the same time to repaglinide 1mg 15min oral meal, 3 times / d. Continuous treatment for 12 weeks. The changes of fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG) and HbA1c were observed and compared before and after treatment. The adverse drug reactions were recorded. Results The total effective rate was 87.1% in the treatment group and 43.3% in the control group, and the therapeutic effect in the treatment group was higher than that in the control group (P <0.01). After treatment, fasting blood glucose, postprandial 2h blood glucose and HbA1c in treatment group were significantly lower than those before treatment (P <0.01 or P <0.05), and were significantly higher than those in control group (P <0.01 or P <0.05) . No obvious adverse drug reactions were observed. Conclusion Repaglinide can effectively control blood glucose and protect the functions of pancreatic β-cells. It is an ideal medicine for clinical treatment of type 2 diabetes mellitus.